Lorenzo Barba

ORCID: 0000-0003-1328-3620
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Alzheimer's disease research and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Dementia and Cognitive Impairment Research
  • Acute Ischemic Stroke Management
  • Stroke Rehabilitation and Recovery
  • Health and Lifestyle Studies
  • Lysosomal Storage Disorders Research
  • Ginkgo biloba and Cashew Applications
  • Cerebrovascular and Carotid Artery Diseases
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Amyotrophic Lateral Sclerosis Research
  • Prion Diseases and Protein Misfolding
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Cerebrospinal fluid and hydrocephalus
  • Neuroscience and Neuropharmacology Research
  • Genetic Neurodegenerative Diseases
  • Alcoholism and Thiamine Deficiency
  • S100 Proteins and Annexins
  • Neurological disorders and treatments
  • Physical Activity and Health
  • Invertebrate Immune Response Mechanisms
  • Biomarkers in Disease Mechanisms
  • Multiple Sclerosis Research Studies
  • Spinal Dysraphism and Malformations
  • Neurological Complications and Syndromes

Martin Luther University Halle-Wittenberg
2022-2025

University Hospital in Halle
2022-2025

University of Perugia
2022

Universität Ulm
2022

University Hospital Ulm
2022

Universitat de Barcelona
1991-2009

Blood phosphorylated (p)-tau 181 and p-tau 217 have been proposed as accurate biomarkers of Alzheimer's disease (AD) pathology. However, blood is also elevated in amyotrophic lateral sclerosis (ALS) without a clearly identified source. We measured serum multicentre cohort ALS (n = 152), AD 111) cases controls 99) recruited from four different centres. Further, we investigated the existence both species using immunohistochemistry (IHC) mass spectrometry (MS) muscle biopsies (IHC: n 13, MS: 5)...

10.1038/s41467-025-57144-7 article EN cc-by Nature Communications 2025-03-05

The European Nutrition and Health Report is the first comprehensive assessment of present status nutrition health in Europe, available resources requirements for compatible representative data from different countries. 13 EU member states Norway have participated this project, pursuing three main goals: Compila

10.1159/isbn.978-3-318-01501-0 article EN Forum of nutrition/Bibliotheca Nutritio et dieta 2005-04-14

Patients with Lewy body disease (LBD) often show a co-occurring Alzheimer (AD) pathology. CSF biomarkers allow the detection in vivo of AD-related pathologic hallmarks included amyloid-tau-neurodegeneration (AT(N)) classification system. Here, we aimed to investigate whether synaptic and neuroaxonal damage are correlated presence AD copathology LBD can be useful differentiate patients different AT(N) profiles.

10.1212/wnl.0000000000207371 article EN Neurology 2023-05-15

Introduction β-synuclein (β-syn) is a presynaptic protein, whose cerebrospinal fluid (CSF) levels are increased in patients with Alzheimer’s diseases (AD) showing mild cognitive impairment (MCI) and dementia (dem). Here, we aimed to investigate CSF β-syn subjects at different AD stages, including preclinical (pre-AD), compare its behaviour another synaptic biomarker, α-synuclein (α-syn), two biomarkers of neuro-axonal damage, namely neurofilament light chain protein (NfL) total tau (t-tau)....

10.1136/jnnp-2022-329124 article EN Journal of Neurology Neurosurgery & Psychiatry 2022-08-09

We aimed to assess the prognostic value of serum β-synuclein (β-syn), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with moderate-to-severe acute ischemic stroke. measured β-syn, GFAP NfL samples collected one day after admission 30 adult stroke due middle cerebral artery (MCA) occlusion. tested associations between biomarker levels clinical radiological scores (National Institute Health Stroke Scale scores, NIHSS, Alberta Program Early CT Score,...

10.1038/s41598-023-47765-7 article EN cc-by Scientific Reports 2023-11-28

ABSTRACT Aims Diagnosis of inclusion body myositis (IBM) is difficult and currently based on a combination clinical (immuno)histological findings. Biomarkers facilitating the diagnostic process are needed. Alpha‐synuclein (αSN) aggregates known histological feature IBM, but there lack information their relevance. Furthermore, serum αSN concentrations in IBM have not been investigated. Methods Immunohistochemical staining for was performed 63 biopsies (19 21 other inflammatory myopathies, 20...

10.1111/nan.70019 article EN cc-by Neuropathology and Applied Neurobiology 2025-05-19

Proenkephalin (PENK) and prodynorphin (PDYN) are peptides mainly produced by the striatal medium spiny projection neurons (MSNs) under dopaminergic signaling. Therefore, they may represent candidate biomarkers in Huntington's disease (HD) Parkinson's (PD), two neurodegenerative diseases characterized atrophy and/or dysfunction.Using an in-house established liquid chromatography-tandem mass spectrometry (LC-MS/MS) method multiple reaction monitoring mode (MRM) we measured cerebrospinal fluid...

10.1007/s00415-022-11187-8 article EN cc-by Journal of Neurology 2022-06-23

We analyzed the longitudinal concentrations and prognostic roles of plasma β-synuclein (β-syn), glial fibrillary acidic protein (GFAP), neurofilament proteins (NfL NfH) in 33 patients with malignant gliomas, who underwent surgical adjuvant therapy. GFAP NfL levels were increased glioblastoma compared to cases other tumors. β-syn, NfH after surgery, whereas decreased at long-term follow-up. β-syn influenced by surgery and/or radiotherapy regimens. significantly associated survival. Plasma...

10.1002/acn3.51878 article EN cc-by-nc-nd Annals of Clinical and Translational Neurology 2023-08-23

Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) non-prion rapidly progressive dementias 106). In fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to lesser extent, total tau 0.92). Further, diagnostic value plasma 0.91) outperformed that 0.79) neurofilament light chain 0.65) was comparable biomarkers. might...

10.1002/acn3.51873 article EN cc-by Annals of Clinical and Translational Neurology 2023-08-08

Introduction: Blood-based biomarkers may improve prediction of functional outcome in patients with acute ischemic stroke. The role neurofilament light chain (NfL) and glial fibrillary acidic (GFAP) as potential especially severe stroke is unknown. Patients Methods: Prospective, monocenter, cohort study including consecutive the anterior circulation on admission (NIHSS score ⩾ 6 points or indication for mechanical thrombectomy). Outcome was assessed 3 months after index by modified Rankin...

10.1177/23969873241234436 article EN cc-by European Stroke Journal 2024-02-24

Although previous studies investigated the main predictors of outcomes after endovascular thrombectomy (EVT) in patients aged 80 years and older, less is known about impact procedural features on elderly patients. The aim this study was to investigate influence EVT technical procedures 3-month a population older.

10.1007/s00415-023-12077-3 article EN cc-by Journal of Neurology 2023-11-20
Coming Soon ...